/PRNewswire/ Arthrosi Therapeutics, Inc., a clinical-stage biotechnology company, has announced they have received written response from the U.S. Food and.
/PRNewswire/ Arthrosi Therapeutics, Inc., a clinical-stage biotechnology company, today announced positive topline results from its Phase 2b clinical study.
/PRNewswire/ Arthrosi Therapeutics, Inc., a clinical-stage biotechnology company, today announced the completion of enrollment for its global Phase 2b.
/PRNewswire/ Arthrosi Therapeutics, Inc., a clinical-stage biotech company announced today patient enrollment in a global phase 2b study of AR882, its novel.